Andrea Vingiani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7098258/publications.pdf Version: 2024-02-01



#	ARTICLE Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and	IF	CITATIONS
1	Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24,	2.4	530
2	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	0.8	505
3	Assessing Tumor-Inflitrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic	2.4	469
4	Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Annals of Oncology, 2016, 27, 249-256.	0.6	125
5	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discovery, 2022, 12, 90-107.	7.7	124
6	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Annals of Oncology, 2019, 30, 236-242.	0.6	123
7	Tumor infiltrating lymphocytes in early breast cancer. Breast, 2018, 37, 207-214.	0.9	108
8	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Research and Treatment, 2016, 158, 323-331.	1.1	100
9	Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nature Medicine, 2018, 24, 1469-1480.	15.2	98
10	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 2021, 11, 2796-2811.	7.7	79
11	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Annals of Oncology, 2017, 28, 321-328.	0.6	72
12	Oncological Outcomes of Nipple-Sparing Mastectomy: A Single-Center Experience of 1989 Patients. Annals of Surgical Oncology, 2018, 25, 3849-3857.	0.7	68
13	Tumor-infiltrating lymphocytes (TILs) in ER+/HER2â^' breast cancer. Breast Cancer Research and Treatment, 2020, 183, 347-354.	1.1	59
14	The clinical relevance of micropapillary carcinoma of the breast: a case–control study. Histopathology, 2013, 63, 217-224.	1.6	53
15	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. Npj Breast Cancer, 2022, 8, 3.	2.3	33
16	Transplantation of autologous extracellular vesicles for cancer-specific targeting. Theranostics, 2021, 11, 2034-2047.	4.6	32
17	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. Cancers, 2020, 12, 112.	1.7	30
18	Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. Cells, 2020, 9, 2644.	1.8	30

ANDREA VINGIANI

#	Article	IF	CITATIONS
19	Towards mm-wave spectroscopy for dielectric characterization of breast surgical margins. Breast, 2019, 45, 64-69.	0.9	28
20	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. Breast, 2015, 24, 290-293.	0.9	27
21	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. Cancers, 2021, 13, 2356.	1.7	26
22	Effect of Metformin on Breast Ductal Carcinoma <i>In Situ</i> Proliferation in a Randomized Presurgical Trial. Cancer Prevention Research, 2015, 8, 888-894.	0.7	23
23	Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. Breast, 2017, 34, 83-88.	0.9	22
24	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. Cancer Letters, 2021, 511, 77-87.	3.2	22
25	Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study. Breast Cancer Research and Treatment, 2020, 184, 723-731.	1.1	20
26	Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. European Journal of Cancer, 2022, 172, 300-310.	1.3	19
27	Analysis of Efficacy and Accuracy of 2 Vacuum-Assisted Breast Biopsy Devices: Mammotome and Elite. Clinical Breast Cancer, 2018, 18, e1277-e1282.	1.1	16
28	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. Cancers, 2019, 11, 1753.	1.7	16
29	Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation. Nanotheranostics, 2021, 5, 1-7.	2.7	13
30	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. Cancers, 2020, 12, 922.	1.7	12
31	A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. Genome Medicine, 2020, 12, 94.	3.6	11
32	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research, 2019, 21, 153.	2.2	10
33	Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. Scientific Reports, 2022, 12, 1470.	1.6	10
34	The Stearoyl-CoA Desaturase-1 (Desat1) in Drosophila cooperated with Myc to Induce Autophagy and Growth, a Potential New Link to Tumor Survival. Genes, 2017, 8, 131.	1.0	9
35	<i>ROS1</i> Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm. JCO Precision Oncology, 2017, 1, 1-9.	1.5	9
36	Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series. Radiotherapy and Oncology, 2019, 133, 68-76.	0.3	9

ANDREA VINGIANI

#	ARTICLE	IF	CITATIONS
37	Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients. Cancers, 2021, 13, 1409.	1.7	9
38	Contrast-enhanced mammography in the evaluation of breast calcifications: preliminary experience. Tumori, 2020, 106, 491-496.	0.6	8
39	Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. European Journal of Cancer, 2017, 87, 164-171.	1.3	7
40	Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients. Current Opinion in Oncology, 2016, 28, 476-483.	1.1	6
41	Solitary thyroid metastasis from colon cancer: a rare case report. Ecancermedicalscience, 2016, 10, 696.	0.6	4
42	ecancermedicalscience. Ecancermedicalscience, 2012, 6, 253.	0.6	3
43	Salivary gland choristoma in large bowel. Endoscopy, 2012, 44, E13-E14.	1.0	3
44	Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast. Modern Pathology, 2020, 33, 1065-1077.	2.9	3
45	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. JCO Precision Oncology, 2022, 6, e2100472.	1.5	2
46	The Pathology Report. , 2017, , 157-168.		1
47	Malignant salivary gland tumours in families with breast cancer susceptibility. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 221-226.	1.4	0
48	The developmental origins of high grade serous ovarian cancer Journal of Clinical Oncology, 2019, 37, e17063-e17063.	0.8	0
49	Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis. Neoplasma, 2022, , .	0.7	0